While it is becoming clear from these studies that distinct ERα driven epigenetic signaling programs distinguish antiestrogen outcome in the therapeutic setting, relatively little is known regarding the antiestrogen-dependent mechanisms that underlie prevention against tumor development. This evidence concerns the gene ESR1 and neoplasm.